CAS No.: 1194506-26-7
Product introduction:Fruquintinib is a potent, highly selective, and orally bioavailable small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3. Discovered and developed by HUTCHMED, the compound specifically targets the tyrosine kinase activity of all three VEGF receptors, representing a key advancement in anti-angiogenic therapy. Initially approved in China in 2018 for metastatic colorectal cancer (mCRC), its clinical potential has been recognized globally. In November 2023, the U.S. FDA granted approval to fruquintinib (brand name Fruzaqla) for the treatment of previously treated mCRC, establishing it as a leading therapy for this refractory patient population. The drug has also received subsequent approvals in the European Union and multiple other countries-. By selectively inhibiting its targets, fruquintinib demonstrates high efficacy with a favorable off-target toxicity profile, distinguishing it from other VEGFR-targeting agents.
CAS No.:1194506-26-7
Fruquintinib is a white to off-white powder with a molecular formula of C₂₁H₁₉N₃O₅ and a molecular weight of 393.39 g/mol. The chemical name is 6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-N,2-dimethyl-1-benzofuran-3-carboxamide. The compound exhibits pH-dependent solubility, with increased solubility under acidic conditions. It is available in pharmaceutical-grade purity (>98%) and is typically stored at -20°C for long-term stability.
Core Functions:
Active pharmaceutical ingredient (API) in Fruzaqla® for the treatment of adult patients with metastatic colorectal cancer (mCRC) after prior chemotherapy and biologic therapy
Research use in oncology for studies of VEGFR inhibition and tumor angiogenesis
Active research compound for investigating combination therapies with immune checkpoint inhibitors (e.g., tislelizumab)
Preclinical and clinical research in gastric cancer, non-small cell lung cancer, breast cancer, and endometrial cancer
Reference standard for analytical method development and quality control in pharmaceutical testing
Contact: Tony
Phone: 008618700976396
E-mail: sales@fulecare.com
Whatsapp:008618700976396
Add: Zhang Ba 6 Road,Hi tech zone,Xi'an Shaanxi Province,China
